Screened 2026-09-09 · the tape above runs as of 09:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
Everpure, Inc. holds its Distribution at $97.06. Consolidating, no directional conviction, held for 42 days.
As held on the ledger · 2026-09-09
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 42 days
Price at the screen
$97.06
Valuation
132.96 trailing · 27.39 forward price to earnings
Values screen
PASS
Beta
1.43
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
3.14%
Below 33%
Interest-bearing debt is just 3.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
4.25%
Below 33%
Cash held in interest-bearing accounts and securities is 4.3% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-09 screen. The gold marker is the market price at the same screen. A 14.4% margin of safety to the base estimate.
Third-party analyst targets: 19 covering, consensus Buy. The average target sits +34% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Tech that quietly moves the everyday
Picture a small firm whose code sits behind the apps people open without thinking twice. Everpure fits that picture, with a moderate moat, 17 percent return on equity and a 24 percent gap between the current price and our fair value. Analysts see room to $94, and the ethical screen raises no flags.
The business posts a forward multiple of 23 times and a slim 6 percent profit margin, yet it still clears our basic hurdles on returns and competitive position. That combination keeps it on the list rather than in the bin, even if the opportunity rating stays at none.
Low margins leave little room for error if growth slows or competition sharpens, and the valuation offers only modest protection. Nothing here screams a bargain, just a steady name that passes the screen without standing out. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
P trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-26Markup$108.55+0.0%Entry 12
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-25Markup$108.55+0.0%Entry 11
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-24Markup$108.55+0.0%Entry 10
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-23Markup$108.55+0.0%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-22Markup$108.55+29.6%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 29.6% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-21Markup$83.74+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-20Markup$83.74+0.0%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-19Markup$83.74+0.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-08Markup$83.74+16.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 16.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it buy, with a mean price target of $90.
2026-07-18Markup$72.17+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it buy, with a mean price target of $90.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
